Jami Taylor

Jamie Taylor is a recognized expert in incentive restructuring and business model innovation for the pharmaceutical industry, with a focus on neglected-disease innovation and access. 

 

While at Johnson & Johnson, Jamie co-founded the company’s Global Public Health organization and established some of its highest-profile partnerships, including the $550-million-dollar  “DREAMS Innovation” partnership with the President’s Emergency Plan for AIDS Relief, or PEPFAR; the pioneering tuberculosis-regimen-redesign partnership with Harvard Medical School, Partners in Health, and Medicines Sans Frontiers; and MDR-TB drug access initiatives with the Global Fund to Fight AIDS, Tuberculosis, and Malaria. She led efforts in the U.S. and Europe to advance transferable exclusivity vouchers for neglected diseases and played a significant role in securing initial U.S. congressional renewals of the Best Practices for Children Act and the Pediatric Research Equity Act.

 

Today, Jamie advises biotech innovators across a broad range of geographies, technologies, and therapeutic areas. Among other positions, she serves on the Advisory Board for Immuna Therapeutics, a mission-driven enterprise working to democratize affordable access to cell and gene therapies in low- and middle-income countries. She is a lecturer on the Economics of Innovation at the MIT Sloan School of Management and serves on the Strategic Advisory Board of the Center for Climate, Health, and the Global Environment (C-CHANGE) at the Harvard T. H. Chan School of Public Health. Jamie holds an MBA from the Kellogg School of Management at Northwestern University, a master’s degree from Harvard University, and a B.A. with Distinction from the University of Virginia.